Strategic partnerships Sana partners with leading medical institutions (e.g., Mayo Clinic) to advance one-time cell therapies, creating collaboration opportunities for co-development, access to clinical data, and joint manufacturing capabilities that can be leveraged for scalable solutions.

One-time therapies The focus on hypoimmune stem cell-derived islets and potential insulin-replacement therapies presents a compelling upsell path for high-value, long-term treatment modalities, suggesting opportunities for premium pricing discussions and risk-sharing models.

Manufacturing focus Sana emphasizes scalable manufacturing and cost considerations, indicating openness to vendors and partners offering scalable biomanufacturing, process optimization, and supply chain solutions to support broad patient access.

Key leadership With a seasoned CSO joining in 2024 and a track record in bringing biologics to registration, engaging the executive team can accelerate strategic dialogues around clinical milestones, capital planning, and collaboration terms.

Clinical momentum Active participation in major diabetes forums and ongoing trials for Type 1 diabetes signals a growing market signal; sales conversations can align with upcoming trial readouts, regulatory milestones, and payer discussions.